Live Feeds
● TRACKER Updated 2d ago · 60 sources tracked

People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study

Patients who switched from injectable GLP-1 medications to oral Wegovy continued losing weight over three months in a real-world telehealth study. The findings, presented at ObesityWeek 2026, come from Novo Nordisk's slate of 26 abstracts that also include CagriSema program analyses and semaglutide data in children aged 6 to under 12. Australia recently approved the tablet formulation for the first time, expanding global access. No head-to-head trial has directly compared the pill and injection; separate trials and an indirect manufacturer-sponsored comparison suggest similar weight loss in adults without diabetes, though type 2 diabetes and the 7.2 mg injection dose change the picture.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (60)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Patients who switched from injectable GLP-1s to oral Wegovy kept losing weight for three months in a real-world telehealth study.
  • ✓ Novo Nordisk presented 26 abstracts at ObesityWeek 2026, including real-world data on Wegovy pill and injection, CagriSema program analyses, and semaglutide injection research in children aged 6 to under 12.
  • ✓ Australia approved the tablet version of Wegovy for the first time.
  • ✓ No trial has directly compared the Wegovy pill and injection; separate trials and a manufacturer-sponsored indirect comparison suggest similar weight loss in adults without diabetes, but type 2 diabetes and the 7.2 mg injection dose change the picture.
🛡️ Source Corroboration: 60 independent reporting domains (80% confidence) ⏱ Read time: ~3 min

What changed

New real-world telehealth data presented at ObesityWeek 2026 shows sustained weight loss for three months after switching from injectable GLP-1s to oral Wegovy.

Live updates

  1. Real-world data: Switching to Wegovy pill from injections sustains weight loss

    Patients who switched from injectable GLP-1 medications to oral Wegovy continued losing weight over three months in a real-world telehealth study. The findings, presented at ObesityWeek 2026, come from Novo Nordisk's slate of 26 abstracts that also include CagriSema program analyses and semaglutide data in children aged 6 to under 12. Australia recently approved the tablet formulation for the first time, expanding global access. No head-to-head trial has directly compared the pill and injection; separate trials and an indirect manufacturer-sponsored comparison suggest similar weight loss in adults without diabetes, though type 2 diabetes and the 7.2 mg injection dose change the picture.

    Why it matters

    The oral version of Wegovy offers a needle-free alternative that could improve adherence for patients reluctant to use injections. Real-world evidence from telehealth settings helps clarify whether efficacy holds outside controlled trials, especially during formulation switches. Regulatory approvals like Australia's signal broadening market availability, while upcoming pediatric data and combination therapy results from the CagriSema program will shape future treatment guidelines.

    What is confirmed

    • Patients who switched from injectable GLP-1s to oral Wegovy kept losing weight for three months in a real-world telehealth study.
    • Novo Nordisk presented 26 abstracts at ObesityWeek 2026, including real-world data on Wegovy pill and injection, CagriSema program analyses, and semaglutide injection research in children aged 6 to under 12.
    • Australia approved the tablet version of Wegovy for the first time.
    • No trial has directly compared the Wegovy pill and injection; separate trials and a manufacturer-sponsored indirect comparison suggest similar weight loss in adults without diabetes, but type 2 diabetes and the 7.2 mg injection dose change the picture.

    Still unconfirmed

    • Real-world telehealth data show patients who switched from injectable GLP-1s to oral Wegovy reported improved outcomes.

    What to watch next

    • Publication of full ObesityWeek 2026 abstracts and peer-reviewed manuscripts on the switch study
    • FDA or EMA regulatory decisions on oral Wegovy labeling expansions
    • CagriSema REDEFINE program Phase 3 readouts expected in 2027
    Sources used for this update (11)
    1. www.onedaymd.com — GLP-1 Studies Explained: The Complete Evidence Guide (2026 ...
    2. healthfactsjournal.com — Wegovy Pill: Effectiveness, Cost, Side Effects & More
    3. www.weightlossrankings.org — Wegovy Pill vs Wegovy Injection: How Close Are the Results?
    4. healthfactsjournal.com — Wegovy Pills Vs Injections: Cost, Side Effects & Results
    5. clearmetabolic.com — Wegovy Pill vs Injection: Which Is Better? - clearmetabolic.com
    6. www.cbsnews.com — GLP-1 drugs, popular for weight loss, get FDA warning of rare vision-loss side effect
    7. pacifictribune.com — Wegovy oral pill switch sustains weight loss, real-world
    8. www.altrx.com — Wegovy Pill Results: Weight Loss Data From the Tablet Trial
    9. www.prnewswire.com — Novo real-world studies link Wegovy® 2.4 mg to reductions in ...
    10. www.treatmentshub.com — GLP-1 Weight Loss Medications 2026: Every Option Compared
    11. www.foxnews.com — Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
    confidence 80%
  2. Novo to Show Real-World Wegovy Pill Data

    Novo Nordisk is scheduled to present 26 abstracts at ObesityWeek 2026, featuring new real-world data on the Wegovy pill and injection, including telehealth settings. The upcoming presentations in Washington, D.C., will also showcase analyses from the CagriSema REDEFINE program and research on semaglutide injections in children aged 6 to under 12. These findings follow recent market approvals, including Australia approving the tablet version of Wegovy for the first time.

    Why it matters

    ObesityWeek 2026 runs from November 14 to November 17 in Washington, D.C., and serves as the primary venue for Novo Nordisk to release its latest obesity portfolio data. Real-world treatment outcomes and pediatric research are shaping corporate growth recovery and expanding global treatment options beyond traditional weekly injections.

    What is confirmed

    • Novo Nordisk will present 26 abstracts at ObesityWeek 2026 in Washington, D.C., from November 14 to 17.
    • The upcoming presentations include real-world treatment experience with the Wegovy pill and injection, incorporating data from telehealth settings.
    • Novo Nordisk's presentations will feature new analyses from the investigational CagriSema REDEFINE program.
    • Research on the investigational semaglutide injection in children ages 6 to under 12 will be presented at ObesityWeek 2026.
    • A tablet version of Wegovy has been approved for the first time in Australia.

    Still unconfirmed

    • Wegovy pill uptake and CagriSema trial results are actively shaping Novo Nordisk's financial growth recovery story.

    What to watch next

    • The official presentation of the 26 abstracts at ObesityWeek 2026 between November 14 and 17
    • Further details regarding the real-world performance of the Wegovy pill in telehealth settings
    Sources used for this update (10)
    1. finance.yahoo.com — Novo to present new CagriSema and Wegovy® data at ObesityWeek ...
    2. healthfactsjournal.com — Wegovy weight loss: Options, Effectiveness, Costs & Safety ...
    3. www.novonordisk-us.com — CagriSema & Wegovy® at ObesityWeek® | Novo Nordisk U.S.
    4. www.marketscreener.com — Novo Nordisk Announces Presentation Of New CagriSema And ...
    5. medicalxpress.com — Australia is set to get a Wegovy pill. How does it compare with weight‑loss injections?
    6. finance.yahoo.com — Novo Nordisk (NVO) Q3 2026 Earnings Call Transcript
    7. www.livemint.com — The iPhone effect in healthcare: How Mounjaro is rewriting the economics of India’s pharma market
    8. vitalhealthmedicalcare.com — Wegovy Pill vs Injection | Results, Routine, and Cost
    9. kymatahealth.com — The Wegovy Pill (Oral Semaglutide): Trials and FDA Label
    10. healthfactsjournal.com — Wegovy pill reviews: Reviews, Results, Cost & What to Know
    confidence 100%
  3. People on Novo's Wegovy pill kept losing weight after switching from obesity injections

    A real-world study found patients who switched to Novo's Wegovy pill from obesity injections continued to lose weight. The study's details were not fully disclosed, but it suggests a significant shift in patient preference towards oral medications. Nearly 149,000 Americans started oral semaglutide within 12 weeks of its launch. The findings will be presented at ObesityWeek 2026.

    Why it matters

    The study's results indicate a potential change in the commercial dynamics between daily oral medications and weekly injections. Novo Nordisk's Wegovy pill has attracted prescriptions quickly since its launch. The company's obesity portfolio, including the Wegovy pill and injection, will be featured in 26 abstracts at ObesityWeek 2026.

    What is confirmed

    • Nearly 149,000 Americans started oral semaglutide within 12 weeks of its launch.
    • Novo Nordisk will present new data on its obesity portfolio, including real-world treatment experience with the Wegovy pill, at ObesityWeek 2026.
    • An analysis followed 194 telehealth patients who moved from injectable semaglutide or tirzepatide to the Wegovy pill.

    Still unconfirmed

    • The analysis measured treatment experience with the Wegovy pill in telehealth settings.

    What to watch next

    • ObesityWeek 2026 presentations
    • Full details of the real-world study on patients switching to Wegovy pill
    Sources used for this update (6)
    1. www.novonordisk.com — Press releases - Novo Nordisk
    2. www.prnewswire.com — Novo to present new CagriSema and Wegovy® data at ObesityWeek ...
    3. www.biospace.com — Novo to present new CagriSema and Wegovy® data at ... - BioSpace
    4. www.nobsrx.com — People Who Switched From GLP-1 Injections to a Pill Averaged ...
    5. www.truveta.com — AMCP Nexus: Early uptake of oral semaglutide for obesity ...
    6. healthfactsjournal.com — Pills Loss Weight: Effectiveness, Cost & Side Effects Guide
    confidence 90%
  4. Wegovy Pill Sees Rapid US Adoption Outpacing Major Injections

    Nearly 149,000 Americans started oral semaglutide within 12 weeks of its launch, according to national data tracking the Wegovy pill in 2026. The oral weight-loss medication attracted prescriptions more quickly than the initial rollout of two major injectable treatments, marking a significant shift in patient preference. Real-world studies are also tracking how patients maintaining weight reductions on the pill manage body mass index and waist circumference over time, altering the commercial dynamics between daily oral medications and weekly injections.

    Why it matters

    The rapid uptake of oral semaglutide follows a December 2025 FDA approval that allowed Novo Nordisk to introduce the pill to the US market. This adoption surge follows weaker sales growth for the company's injectable medications and offers a new option for long-term weight maintenance. Researchers are evaluating everyday usage patterns to understand how transitioning from injections to daily pills impacts patient outcomes.

    What is confirmed

    • Nearly 149,000 Americans started oral semaglutide within 12 weeks.
    • Early growth of the semaglutide pill was steeper than the initial uptake of two major injectable weight-management treatments.

    Still unconfirmed

    • Patients switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study.

    What to watch next

    • Long-term observational study results tracking body mass index, weight, and waist circumference over two years
    • Further data on how oral semaglutide compares directly to injections in real-world clinical practice
    Sources used for this update (4)
    1. joeymed.com — The Wegovy Pill's Fast Start in 2026: What New Data on ...
    2. healthfactsjournal.com — Wegovy Pill Reviews: Real Results & Does It Work?
    3. ctv.veeva.com — A Two-year Prospective, Observational Study of Wegovy in Real ...
    4. knowridge.com — Why people choose new weight-loss pill over injectable treatments
    confidence 90%
  5. Novo Nordisk Stakes Claim in Oral Obesity Market

    Patients transitioning to oral weight-loss medications maintain substantial portions of their initial reductions. Following a December 2025 FDA approval, oral semaglutide uptake among eligible US adults climbed rapidly within three months, approaching the adoption rates of injectable treatments. Novo Nordisk released new oral GLP-1 data to strengthen its position in the obesity market after reporting weaker sales growth for its injectable medications. This real-world evidence highlights how individuals manage long-term weight maintenance when shifting away from weekly injections to daily pills, altering the commercial dynamics between oral and injectable therapies.

    Why it matters

    Novo Nordisk is pushing into the pill market following slower sales growth for its injectable GLP-1 drugs. Oral semaglutide gained FDA approval in December 2025 and saw rapid adoption among millions of eligible adults in the United States. This shift offers patients a daily routine alternative to injections, prompting comparative evaluations of trial results, costs, and side effects against established treatments like Zepbound.

    What is confirmed

    • Oral semaglutide initiation climbed quickly after its December 2025 FDA approval among nearly 48 million US adults eligible for obesity medications.
    • Novo Nordisk reported weaker sales growth for its injectable GLP-1 drugs.

    Still unconfirmed

    • Oral semaglutide uptake reached near injectable levels within three months of approval.

    What to watch next

    • Long-term sales performance data comparing oral semaglutide against injectable treatments
    • Further clinical studies evaluating cost and side effect trade-offs between pills and injections
    Sources used for this update (4)
    1. pharmaphorum.com — Novo Nordisk fights back with oral GLP-1 data in obesity
    2. www.ajmc.com — Oral Semaglutide Uptake Near Injectable Levels Within 3 ...
    3. www.treatmentshub.com — GLP-1 Pills vs Injections (2026): Results, Cost & Routine
    4. creators.yahoo.com — Wegovy pill or Wegovy shot? A doctor explains how they ...
    confidence 95%
  6. Patients Maintain Weight Loss After Switching to Oral Obesity Drugs

    Adults transitioning from injectable weight-loss treatments to daily oral medications successfully maintain significant portions of their initial weight reduction. A recent trial demonstrated that patients shifting from tirzepatide or semaglutide to daily orforglipron retained between 75 and 79 percent of their lost weight over the course of a year. This performance significantly outpaced placebo groups, which retained only 38 to 49 percent of their lost weight. These findings provide additional clinical insight into how patients manage long-term weight maintenance when moving away from weekly injections.

    Why it matters

    Weight-loss treatment plans frequently require transitions between different delivery methods due to patient preference or drug availability. Evaluating how oral formulations perform following initial injectable regimens is crucial for long-term obesity management. Clinical trials continue to test alternative daily pills to establish reliable maintenance protocols.

    What is confirmed

    • Adults switched from tirzepatide or semaglutide to daily orforglipron kept 75 to 79 percent of lost weight over a year.
    • Placebo groups in the trial kept 38 to 49 percent of lost weight over the same period.
    • The trial evaluating orforglipron maintenance after injectables included 376 persons.

    What to watch next

    • Long-term real-world effectiveness data comparing different oral obesity pills
    • Direct comparative studies between oral orforglipron and oral semaglutide
    Sources used for this update (2)
    1. fitnesshealthandnutrition.com — Orforglipron After Zepbound or Wegovy: 75–79% of Loss Kept
    2. remyresearch.com — Oral GLP-1 for Weight Loss 2026: Foundayo, VK2735 | Remy Research
    confidence 100%
  7. Wegovy Pill Data Shows Continued Weight Loss After Switching

    Adults transitioning from weekly weight-loss injections to Novo Nordisk's oral Wegovy pill continue to lose weight, dropping an average of 4.1 percent of their body weight over three months. Data from the observational OCTANE study, presented at the 2026 European Association for the Study of Diabetes meeting, involved 194 individuals who switched from weekly injections. This real-world signal indicates that patients do not necessarily experience weight regain when moving to the daily oral formulation. Concurrently, early uptake data shows weekly starts of the oral semaglutide pill matched the injection within 12 weeks among US records.

    Why it matters

    The data strengthens Novo Nordisk's position in the competitive obesity treatment market against rivals like Eli Lilly. These findings help address whether patients can maintain their weight loss regimens when transitioning from painful weekly injections to a convenient daily pill format. However, the observational findings stem from a retrospective analysis lacking a formal comparator group and peer review, relying instead on self-reported weights from a telehealth platform.

    What is confirmed

    • Adults who switched from weekly injections to the Wegovy pill lost an average of an additional 4.1 percent of body weight over three months.
    • The OCTANE study analyzed de-identified data from the Ro telehealth platform.
    • Novo Nordisk reported the findings at the 2026 European Association for the Study of Diabetes meeting.

    Still unconfirmed

    • Records of 48 million US adults show weekly starts of the semaglutide pill matched the injection within 12 weeks, with half the starters being new to GLP-1 drugs.

    What to watch next

    • Peer-reviewed publication of the OCTANE study data.
    • Further updates on oral semaglutide uptake and real-world adherence rates.
    Sources used for this update (4)
    1. belite.com — Switching From Wegovy or Zepbound Injections to the Wegovy ...
    2. medicalupdateonline.com — People switching from weight-loss injections to Wegovy pill ...
    3. www.peptidereviewdesk.com — Wegovy pill uptake: 148,792 starts in 12 weeks
    4. pharmaphorum.com — Novo Nordisk says oral Wegovy hits weight loss goal
    confidence 90%
  8. Novo Nordisk Promotes Oral Wegovy Efficacy Data at ECO

    Adults with obesity who switch from injectable GLP-1 treatments to Novo Nordisk's daily oral semaglutide pill continue to lose weight, according to observational OCTANE study data. Patients staying on the pill for three months achieve an average weight loss of 4.1 percent, representing 8.8 pounds from an average starting weight of 221.6 pounds. While the observational findings suggest patients can transition to oral options for convenience, experts caution that the analysis is retrospective, lacks a comparator group and peer review, and relies on self-reported weights.

    Why it matters

    The data highlights an industry-wide push into oral maintenance therapies following initial weight loss injections. Novo Nordisk presented oral Wegovy efficacy data at the ECO conference, competing directly with Eli Lilly as companies build cases for oral treatments during the maintenance phase. A Savannah physician has also noted that injections still work better than the oral pill.

    What is confirmed

    • Adults with obesity who switched from injectable GLP-1 medications to Novo Nordisk's daily oral semaglutide pill continued losing weight.
    • Patients staying on the pill for three months saw an average weight loss of 4.1 percent, or 8.8 pounds from an average starting weight of 221.6 pounds.

    Still unconfirmed

    • Injections still work better than the oral pill according to a Savannah physician.
    • Eli Lilly is building the case for switching to Foundayo in the maintenance phase after injectables.

    What to watch next

    • Peer review publication of the OCTANE study data
    • Further comparative data readouts from ECO and competing pharmaceutical firms
    Sources used for this update (5)
    1. www.biospace.com — Obesity - BioSpace
    2. pharmaphorum.com — Novo, Lilly trade oral GLP-1 data readouts at ECO
    3. scale-solutions.com — Wegovy Pill vs Injection: Does the Pill Work as Well?
    4. www.thepharmaletter.com — Pharma and Biotechnology Events and Conferences | The ...
    5. dictionary.cambridge.org — PEOPLE | definition in the Cambridge English Dictionary
    confidence 90%
  9. Wegovy Pill Study Shows Weight Loss After Switching From Injections

    Adults with obesity who switched from injectable GLP-1 medications to Novo Nordisk's daily oral semaglutide pill continued losing weight. Patients staying on the pill for three months saw an average weight loss of 4.1 percent, which equals 8.8 pounds from an average starting weight of 221.6 pounds. The observational study, known as OCTANE, suggests patients can move to oral therapies for convenience without stopping their weight loss progress. However, experts note that the analysis is retrospective, relied on self-reported weights, and lacks a comparator group or peer review.

    Why it matters

    The OCTANE study was presented at the European Association for the Study of Diabetes meeting in Milan. The findings offer a potential pathway off weekly injections for patients managing obesity. Independent analysis points out that the study size and follow-up duration require careful evaluation to fully assess the strength of the results.

    What is confirmed

    • Adults with obesity who switched from injectable GLP-1 medications to the oral semaglutide pill continued losing weight, seeing an average weight loss of 4.1% over three months.
    • The OCTANE study analysis was presented at the EASD meeting in Milan.
    • Patients lost an average of 8.8 pounds from an average starting weight of 221.6 pounds.

    Still unconfirmed

    • The analysis was retrospective, weights were self-reported, and the results have not been peer-reviewed.

    What to watch next

    • Peer-reviewed publication of the OCTANE study data
    • Longer-term follow-up studies comparing oral semaglutide directly to continuation of injectable GLP-1 therapy
    Sources used for this update (15)
    1. nypost.com — people magazine | Latest News | New York Post
    2. pocketmags.com — People Magazine Subscriptions and 05-10-2026 Issue - Pocketmags
    3. www.dictionary.com — PEOPLE Definition & Meaning | Dictionary.com
    4. www.patientcareonline.com — Switch to Oral Semaglutide Linked to 4.1% Weight Loss at 3 Months in New Study
    5. www.healthline.com — Switching from GLP-1 Injections to Wegovy Pill Shows Additional Weight Loss of 4.1%
    6. www.medicaldaily.com — Patients Who Switched from Weight-Loss Shots to the Wegovy ...
    7. finance.yahoo.com — Novo's Wegovy Pill Shows Weight Loss After Switching From ...
    8. joeymed.com — Switching From Weight Loss Injections to the Wegovy Pill ...
    9. biotech-insider.com — Wegovy Pill Study Points to a Path Off Weekly Injections
    10. pharma.economictimes.indiatimes.com — Wegovy Pill Outperforms Injections in Weight Loss, Study ...
    11. www.europesays.com — Wegovy® Pill OCTANE Study at EASD - Denmark
    12. www.europesays.com — Novo's Wegovy Pill Shows Weight Loss After Switching From ...
    confidence 90%
  10. Oral semaglutide maintains weight loss after injectable therapy

    Adults with obesity who switched from injectable GLP-1 medications to Novo Nordisk's daily oral semaglutide pill continued losing weight. Patients staying on the pill for three months saw an average weight loss of 4.1%, which equals 8.8 pounds from an average starting weight of 221.6 pounds. The study suggests patients can move to oral therapies for convenience without stopping their weight loss progress.

    Why it matters

    This transition offers an alternative to lifelong weekly injections. It addresses patient preference for oral medication over needles.

    What is confirmed

    • Patients switching to the oral semaglutide pill for three months lost an average of 8.8 pounds.
    • The average starting weight for participants in the study was 221.6 pounds.
    • The average weight loss for those on the oral pill was 4.1%.

    What to watch next

    • Long-term weight maintenance data beyond the three-month window
    • Comparison of oral semaglutide efficacy against continued injectable use
    Sources used for this update (2)
    1. en.wikipedia.org — People (magazine) - Wikipedia
    2. www.youtube.com — People - YouTube
    confidence 100%
  11. Wegovy Pill Maintained Weight Loss After Injection Switch

    Adults with overweight or obesity who transitioned from injectable GLP-1 weight-loss medications to Novo Nordisk's once-daily oral semaglutide pill continued to drop pounds in a real-world study. Patients who remained on the Wegovy pill for three months achieved an average weight loss of 4.1%, equivalent to 8.8 pounds from an average starting weight of 221.6 pounds. The data indicates patients may not require weekly injections indefinitely and can transition to more convenient oral therapies without halting their progress.

    Why it matters

    The findings stem from the OCTANE study, which analyzed de-identified data from the Ro telehealth platform and was presented at EASD2026. The research collaboration between Ro and Novo Nordisk seeks to generate real-world evidence for the oral treatment option. Medical professionals observe that this flexibility addresses long-term management preferences for individuals using GLP-1 medications.

    What is confirmed

    • Patients with overweight or obesity who switched from injectable GLP-1 therapies to the once-daily oral semaglutide Wegovy pill and stayed on treatment for three months lost an average of 4.1% or 8.8 pounds.
    • The analysis was based on an average starting weight of 221.6 pounds among participants in the OCTANE study.
    • The OCTANE study analyzed de-identified data drawn from the Ro telehealth platform.

    What to watch next

    • Further clinical data on long-term adherence and weight maintenance beyond the initial three-month window.
    • Additional real-world evidence initiatives arising from the Ro and Novo Nordisk research collaboration.
    Sources used for this update (14)
    1. Reuters — Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
    2. CNBC — People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
    3. qz.com — Switching to Novo Nordisk's weight loss pill helped people keep shedding pounds
    4. PR Newswire — Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovy® Pill
    5. marketscreener.com — Oral Wegovy option confirms its effectiveness in real-world data
    6. finance.yahoo.com — Novo Nordisk Wegovy pill weight loss switch study results
    7. Pharmaceutical Executive — Peptide Ruling Stalls | PharmExec
    8. FirstWord Pharma — EASD26: Novo says people switching from injectable GLP-1s to oral Wegovy continue losing weight
    9. STAT — Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
    10. www.cnbc.com — Novo's Wegovy pill improves weight loss after switch from ...
    11. www.prnewswire.com — People switching from weight-loss injections to Novo's Wegovy ...
    12. www.biospace.com — People switching from weight-loss injections to Novo's Wegovy ...
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community